Abingworth brings in new leadership
This article was originally published in Clinica
Abingworth, the international investment group focused on healthcare and life sciences, has appointed Tim Haines and Kurt von Emster joint managing partners. They succeed Stephen Bunting, who takes on the role of chairman. Mr Haines, who is based in London, has been with Abingworth since 2005, while Mr von Emster, based in California, joined the firm in January this year. Mr Bunting commented that the “new and younger leadership will build on all that has been achieved to date with new insights and energy”. Abingworth has funds under management of voer $1.25bn. Its medtech investments in its latest Bioventures VI fund include corneal crosslinking specialist Avedro and medical imaging company Median Technologies. Other medtech companies in Abingworth’s portfolio have included, among others, Lombard Medical and Epigenomics, who both went public, and Pathwork Diagnostics, which was acquired by Response Genetics.